Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1473-1480

  Jeansonne, Duane P ^a   Koh, Gar Yee ^a   Zhang, Fang ^a   Kirk Ballard, Heather ^b   Wolff, Laura ^a   Liu, Dong ^a   Eilertsen, Kenneth ^b   Liu, Zhijun ^a  

^a LOUISIANA STATE UNIVERSITY AGRICULTURAL CENTER   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Antagonism; Apoptosis; Camptothecin; Cancer; Paclitaxel; Synergism

Indexed keywords

BCL 2 LIKE 10 PROTEIN; CAMPTOTHECIN; FLICE INHIBITORY PROTEIN; PACLITAXEL; PROTEIN HIP1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DITERPENES, KAURANE; DRUG STABILITY; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSIDES; HL-60 CELLS; HUMANS; PACLITAXEL; PANCREATIC NEOPLASMS; SOLVENTS;

EID: 79953057643     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1187     Document Type: Article

References (26)

1. Mekhail TM and Markman M: Paclitaxel in cancer therapy. Expert Opin Pharmacother 3: 755-766, 2002. (Pubitemid 34649705)
2. Oliveras-Ferraros C, Vazquez-Martin A, Colomer R, De Llorens R, Brunet J and Menendez JA: Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling. Int J Oncol 32: 113-120, 2008. (Pubitemid 351176068)
3. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156, 1999. (Pubitemid 29449089)
4. Wang TH, Wang HS and Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628, 2000.
5. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM and Brem H: Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6: 609-621, 2007. (Pubitemid 351308218)
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
7. Haddad R, Sonis S, Posner M, et al: Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/ paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 115: 4514-4523, 2009.
8. Stathopoulos GP, Dimitroulis J, Antoniou D, et al: Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small cell lung cancer: a phase I-II trial. Br J Cancer 93: 1106-1111, 2005. (Pubitemid 41670693)
9. Thomas CJ, Rahier NJ and Hecht SM: Camptothecin: current perspectives. Bioorg Med Chem 12: 1585-1604, 2004.
10. Basili S and Moro S: Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Pat 19: 555-574, 2009.
11. Kingsbury WD, Boehm JC, Jakas DR, et al: Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107, 1991.
12. Sawada S, Okajima S, Aiyama R, et al: Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull (Tokyo) 39: 1446-1450, 1991.
13. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985. (Pubitemid 16211028)
14. Lorence A and Nessler CL: Camptothecin, over four decades of surprising findings. Phytochemistry 65: 2735-2749, 2004. (Pubitemid 39330172)
15. Ramalingam SS, Foster J, Gooding W, Evans T, Sulecki M and Belani CP: Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. Cancer 116: 1344-1349, 2010.
16. Younes A, Preti HA, Hagemeister FB, et al: Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 12: 923-927, 2001. (Pubitemid 32725763)
17. Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994. (Pubitemid 24330215)
18. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734-741, 1996. (Pubitemid 26195021)
19. Jonsson E, Fridborg H, Nygren P and Larsson R: Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 54: 509-514, 1998. (Pubitemid 28487370)
20. Trubetskoy O, Marks B, Zielinski T, Yueh MF and Raucy J: A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. AAPS J 7 E6-E13, 2005. (Pubitemid 41554304)
21. Hoffmann J, Vitale I, Buchmann B, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68: 5301-5308, 2008.
22. Judson PL, Watson JM, Gehrig PA, Fowler WC Jr and Haskill JS: Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 59: 2425-2432, 1999. (Pubitemid 29242292)
23. Reinicke KE, Kuffel MJ, Goetz MP and Ames MM: Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemother Pharmacol 66: 575-583, 2009.
24. Kang HJ, Lee SH, Price JE and Kim LS: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J 15: 223-229, 2009.
25. Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A and Budillon A: Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 8: 3075-3087, 2009.
26. Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204, 2010.